Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Supriya Lifescience IPO is 48. Their analysis recommends May Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 48 | May Subscribe |
[Dilip Davda] SLL has been making strides with higher top and bottom lines year after year and exporting over 75% of products to more than 86 countries. Based on financial parameters, the issue is attractively priced leaving something on the table across the board. The issue is worth considering for short to long term rewards. Read detail review...
Supriya Lifescience IPO Reviews, analysis and views by popular members. Read Supriya Lifescience Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP